Multimodal Prehabilitation for Gastric Cancer Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-arm phase II trial evaluates a multimodal prehabilitation program started two weeks before curative gastric cancer surgery and continued for three weeks after. The intervention bundles structured exercise, nutrition, and psychological support to modulate the postoperative inflammatory response, as measured by trajectories of markers like CRP. Eligible adults with non-metastatic gastric or esophagogastric junction cancer planning laparoscopic, robotic, or open approaches may participate if they can tolerate oral intake and comply with a home-based component. The study aims to determine feasibility, adherence, and signals of reduced inflammatory burden that could translate into fewer complications and faster recovery. Results will inform whether this approach improves post-surgical immune and recovery parameters compared with historical expectations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult patients (22 to 99 years).
2. Histologically confirmed gastric or esophagogastric junction cancer (Siewert type II/III).
3. Scheduled for curative surgery (laparoscopic or robotic subtotal, total, or proximal gastrectomy).
4. No distant metastasis (M0).
5. Tolerating oral intake.
6. Limited esophageal involvement (≤2 cm), no duodenal invasion. 6.7. Patients with musculoskeletal limitations (exercises will be adopted accordingly) 7.8. Informed consent provided and capable of complying with home-based program.

8.9. No indication for total parenteral or tube feeding. 9.10. ECOG status compatible with intervention. 10.11. ASA class I-III.

Exclusion Criteria:

1. Cognitive impairment, dementia, or psychiatric illness preventing consent or compliance.
2. Emergency surgery or intraoperative conversion to open surgery.
3. Need for preoperative enteral or parenteral feeding.
4. Severe comorbidities requiring multiple organ resection (except cholecystectomy).
5. Allergy or intolerance to components of the ONS product.
6. Severe mMotor impairments affecting ability to perform exercises or complete outcome assessments.
7. Patients under palliative care or rejecting curative treatment.
8. Pregnant and lactating females
9. Existing active electronic implants (e.g., pacemaker, defibrillator) or electromechanical medical device (e.g. insulin pump)
10. Inflamed areas or skin eruptions on the legs

Where it's running

• National University Hospital
  Singapore, Singapore Recruiting

Study contacts

• Study coordinator: Jimmy Bok Yan So, Prof.
• Email: sursbyj@nus.edu.sg
• Phone: 69082222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TEAS after gastrectomy to aid recovery after laparoscopic stomach cancer surgery

  A randomized trial tests whether transcutaneous electrical acupoint stimulation (TEAS) after laparoscopic gastrectomy helps people recover faster and with less pain compared with a sham treatment.

  Recruiting at 8 sites The Affiliated Hospital of Qingdao University · Qingdao, Shandong and 7 other locations · NCT07898293

• Anti-PD-1 with chemotherapy and intraperitoneal nab-paclitaxel for untreated advanced gastric cancer with ascites

  This study tests whether adding anti-PD-1 therapy to standard chemotherapy plus intraperitoneal nab-paclitaxel can help patients with untreated advanced gastric cancer and malignant ascites.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07855640

• Preoperative functional optimization for adults undergoing major cardiac or abdominal surgery

  This study tests a four‑week prehabilitation program to improve fitness before elective major cardiac or abdominal surgery.

  Recruiting ASST Sette Laghi · Varese, VA and 1 other locations · NCT07851350

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.